1 2 3

Table of Contents



I.  List of Tables . . . . . . . . . . . . . . . . . . . . . . vi



II.  Executive Overview. . . . . . . . . . . . . . . . . . . . .1



III. Introduction. . . . . . . . . . . . . . . . . . . . . . . .5



IV.  Major Disease Categories and Market Sizes . . . . . . . . .9

     Atherosclerosis . . . . . . . . . . . . . . . . . . . . . 10

     Thrombosis. . . . . . . . . . . . . . . . . . . . . . . . 13

     Heart Attack. . . . . . . . . . . . . . . . . . . . . . . 14

     Stroke. . . . . . . . . . . . . . . . . . . . . . . . . . 16

     World Market Sizes. . . . . . . . . . . . . . . . . . . . 17



V.  Products in Development. . . . . . . . . . . . . . . . . . 19

     Introduction: Types of Products . . . . . . . . . . . . . 19

     Diagnostic Products in Development for Specific Conditions21

          Heart Attack . . . . . . . . . . . . . . . . . . . . 21

               Creatine kinase-MB, myoglobin and troponin

                    I/troponin T

               Fatty acid binding protein (FABP)

               Anti-streptokinase antibodies

          Congestive Heart Failure (CHF) . . . . . . . . . . . 26

               Brain natriuretic peptide (BNP)

               N-terminal pro-atrial natriuretic peptide (N-ANP)

               Immune molecules

          Atherosclerosis. . . . . . . . . . . . . . . . . . . 29

               Homocysteine

               Activated factor XII

               C-reactive protein

          Stroke and Cardiac Arrest. . . . . . . . . . . . . . 34

     Prognostic Products for Specific Conditions . . . . . . . 36

          Atherosclerosis. . . . . . . . . . . . . . . . . . . 37

               Chlamydia pneumoniae

               Helicobacter pylori

               Herpes virus

               von Willebrand factor

               Leptin

               Remnant-like particle cholesterol

               Genes

          Thrombosis . . . . . . . . . . . . . . . . . . . . . 43

               Soluble fibrin

               Activated factor VII

               Anti-=FE2 glycoprotein-1 antibodies

               Tissue plasminogen activator

               Urinary albumin

               Plasma renin

          Restenosis . . . . . . . . . . . . . . . . . . . . . 47

          Hypertension . . . . . . . . . . . . . . . . . . . . 48

               Angiotensinogen gene

               Epithelial sodium channel gene=20

          Other Conditions . . . . . . . . . . . . . . . . . . 49

               Arrhythmia

               Late-Onset Familial Hypertrophic Cardiomyopathy

               Hereditary Hemochromatosis



VI.  Organizational Activities . . . . . . . . . . . . . . . . 51

     American Biogenetic Sciences Inc. . . . . . . . . . . . . 51

     American Society of Hypertension. . . . . . . . . . . . . 51

     Atherogenics Inc. . . . . . . . . . . . . . . . . . . . . 52

     Axis Biochemicals . . . . . . . . . . . . . . . . . . . . 52

     BioResearch Ireland . . . . . . . . . . . . . . . . . . . 52

     Biosite Diagnostics Inc.. . . . . . . . . . . . . . . . . 53

     BiosPacific . . . . . . . . . . . . . . . . . . . . . . . 53

     Boehringer Mannheim . . . . . . . . . . . . . . . . . . . 54

     Brigham & Women's Hospital. . . . . . . . . . . . . . . . 54

     Competitive Technologies Inc. . . . . . . . . . . . . . . 55

     Consorzio Mario Negri Sud . . . . . . . . . . . . . . . . 56

     Drew Scientific Ltd.. . . . . . . . . . . . . . . . . . . 56

     First Medical Inc.. . . . . . . . . . . . . . . . . . . . 56

     Fortron Bio Science Inc.. . . . . . . . . . . . . . . . . 56

     Harvard Medical School. . . . . . . . . . . . . . . . . . 57

     H=93pital Cardiologique . . . . . . . . . . . . . . . . . 57

     IGEN International Inc. . . . . . . . . . . . . . . . . . 58

     Imperial College. . . . . . . . . . . . . . . . . . . . . 58

     Institute for Chemo- and Biosensors . . . . . . . . . . . 58

     Japan Immunoresearch Laboratories/Otsuka Pharmaceutical Co.59

     Lumenal Technologies. . . . . . . . . . . . . . . . . . . 59

     Mayo Medical School . . . . . . . . . . . . . . . . . . . 60

     Medical Science Systems Inc.. . . . . . . . . . . . . . . 60

     Myriad Genetics Inc.. . . . . . . . . . . . . . . . . . . 60

     Scios Inc.. . . . . . . . . . . . . . . . . . . . . . . . 61

     Shield Diagnostics Ltd. . . . . . . . . . . . . . . . . . 61

     Skye Pharmatech Inc.. . . . . . . . . . . . . . . . . . . 63

     SmithKline Beecham Inc. . . . . . . . . . . . . . . . . . 63

     Spectral Diagnostics Inc. . . . . . . . . . . . . . . . . 64

     University College. . . . . . . . . . . . . . . . . . . . 65

     Yale Univ.. . . . . . . . . . . . . . . . . . . . . . . . 65



VII.  Cardiovascular Drugs in Development. . . . . . . . . . . 67

     Angina. . . . . . . . . . . . . . . . . . . . . . . . . . 67

     Arrhythmias . . . . . . . . . . . . . . . . . . . . . . . 68

     Atherosclerosis and vascular disease. . . . . . . . . . . 68

     High cholesterol and other lipid disorders. . . . . . . . 68

     Heart failure and cardiac insufficiency . . . . . . . . . 69

     Hypertension. . . . . . . . . . . . . . . . . . . . . . . 70

     Hypotension . . . . . . . . . . . . . . . . . . . . . . . 70

     Ischemia-reperfusion injury . . . . . . . . . . . . . . . 71

     Restenosis. . . . . . . . . . . . . . . . . . . . . . . . 71

     Stroke. . . . . . . . . . . . . . . . . . . . . . . . . . 71

     Thrombosis, heart attack and pulmonary embolism . . . . . 71

     Heart transplant rejection. . . . . . . . . . . . . . . . 74

     Other cardiovascular disorders. . . . . . . . . . . . . . 74



Appendix I: Contact Information. . . . . . . . . . . . . . . . 75



Appendix II:  Further Reading. . . . . . . . . . . . . . . . . 79



Index. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81

1 2 3